CD274 and neoplasm: When patients were divided into three categories according to tumor expression levels of PD‐L1, the nivolumab arm had a numerically longer median OS for each category vs. the placebo arm (<1%/indeterminate: 31.0 vs. 22.8 months; 1%–49%: 30.8 vs. 22.7 months; ≥50%: 31.2 vs. 26.6 months; Figure 3).